BofA lowered the firm’s price target on Elevance Health to $580 from $620 and keeps a Buy rating on the shares. MCOs were pressured in 2023 from sector rotation, heightened regulatory scrutiny, trend concerns, and deal uncertainty, but broadly the firm remains bullish on managed care and sees 2024 being about the group resetting expectations, getting back to consistent beats and raises and working through overhangs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELV:
- Elevance Health price target lowered to $552 from $569 at JPMorgan
- Cigna price target raised to $351 from $345 at Deutsche Bank
- Elevance Health files automatic mixed securities shelf
- Elevance Health price target lowered to $555 from $585 at TD Cowen
- Elevance Health reports Medical membership totaled ~47.3M at Sept. 30